 |
20 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- || methylphenidate tablet / Generic mfg.
Clinical, Journal: The Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test. (Pubmed Central) - Jul 10, 2021
TOVA-PR has an index-specific profile compared with CAARS-PR and TOVA-MPH-R. The partial correlation of TOVA-PR with CAARS-PR suggests that a composite score of TOVA specific indices and CAARS could have a synergic impact to improve the reliability of the response assessment in adult ADHD.
- | metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment change, Trial termination, Trial primary completion date: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD (clinicaltrials.gov) - Jan 19, 2017
P3, N=283, Terminated, Sponsor: Alcobra Ltd.
The partial correlation of TOVA-PR with CAARS-PR suggests that a composite score of TOVA specific indices and CAARS could have a synergic impact to improve the reliability of the response assessment in adult ADHD. N=750 --> 283 | Suspended --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2017; FDA Clinical hold
- || metadoxine extended-release (MG01CI) / Arcturus Therap
Trial suspension: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD (clinicaltrials.gov) - Sep 30, 2016
P3, N=750, Suspended, Sponsor: Alcobra Ltd.
N=750 --> 283 | Suspended --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2017; FDA Clinical hold Recruiting --> Suspended
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Jul 6, 2016
P2, N=62, Completed, Sponsor: Alcobra Ltd.
Recruiting --> Suspended Active, not recruiting --> Completed
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Trial primary completion date: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD (clinicaltrials.gov) - Apr 15, 2016
P3, N=750, Recruiting, Sponsor: Alcobra Ltd.
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Oct 2016
- |||||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment open, Trial primary completion date: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD (clinicaltrials.gov) - Aug 17, 2015
P3, N=750, Recruiting, Sponsor: Alcobra Ltd.
Trial primary completion date: Apr 2016 --> Oct 2016 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Apr 2016
- ||||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment closed: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD (clinicaltrials.gov) - Jul 23, 2015
P3, N=750, Active, not recruiting, Sponsor: Alcobra Ltd.
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Apr 2016 Not yet recruiting --> Active, not recruiting
- |||||||||| metadoxine extended-release (MG01CI) / Arcturus Therap
New P3 trial: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD (clinicaltrials.gov) - Jun 23, 2015
P3, N=750, Not yet recruiting, Sponsor: Alcobra Ltd.
- ||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment closed: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Mar 27, 2015
P2, N=60, Active, not recruiting, Sponsor: Alcobra Ltd.
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects (clinicaltrials.gov) - Mar 5, 2015
P2, N=83, Completed, Sponsor: Alcobra Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) (clinicaltrials.gov) - Mar 5, 2015
P2/3, N=300, Completed, Sponsor: Alcobra Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment open: Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects (clinicaltrials.gov) - Sep 5, 2014
P2, N=82, Recruiting, Sponsor: Alcobra Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| metadoxine extended-release (MG01CI) / Arcturus Therap
New P2 trial: Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects (clinicaltrials.gov) - Jul 15, 2014
P2, N=82, Not yet recruiting, Sponsor: Alcobra Ltd.
- ||||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment closed: A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) (clinicaltrials.gov) - Jul 15, 2014
P2/3, N=300, Active, not recruiting, Sponsor: Alcobra Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment open: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Jul 12, 2014
P2, N=60, Recruiting, Sponsor: Alcobra Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || metadoxine extended-release (MG01CI) / Arcturus Therap
Trial primary completion date: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - May 17, 2014
P2, N=60, Not yet recruiting, Sponsor: Alcobra Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Dec 2014
- ||||| metadoxine extended-release (MG01CI) / Arcturus Therap
New P2 trial: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Apr 28, 2014
P2, N=60, Not yet recruiting, Sponsor: Alcobra Ltd.
- |||||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment open: A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) (clinicaltrials.gov) - Mar 9, 2014
P2/3, N=300, Recruiting, Sponsor: Alcobra Ltd.
Trial primary completion date: Jan 2015 --> Dec 2014 Not yet recruiting --> Recruiting
- |||||||||| metadoxine extended-release (MG01CI) / Arcturus Therap
New P2/3 trial: A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=300, Recruiting, Sponsor: Alcobra Ltd.
- | metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Jan 12, 2014
P2, N=36, Completed, Sponsor: Alcobra Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- | metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers (clinicaltrials.gov) - Oct 21, 2013
P1, N=16, Completed, Sponsor: Alcobra Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- | metadoxine extended-release (MG01CI) / Arcturus Therap
New P1 trial: A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers (clinicaltrials.gov) - Sep 2, 2013
P1, N=16, Completed, Sponsor: Alcobra Ltd.
- | metadoxine extended-release (MG01CI) / Arcturus Therap
Trial initiation date: Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Aug 25, 2013
P2, N=36, Completed, Sponsor: Alcobra Ltd.
Active, not recruiting --> Completed Initiation date: Nov 2012 --> Aug 2013
- | metadoxine extended-release (MG01CI) / Arcturus Therap
New P2 trial: Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Sep 12, 2012
P2, N=36, Completed, Sponsor: Alcobra Ltd.
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Mar 25, 2012
P2, N=120, Completed, Sponsor: Alcobra Ltd.
Initiation date: Nov 2012 --> Aug 2013 Recruiting --> Completed